Tag: Dermatologic Surgery

All

Revance's investigational injectable—RT002—achieves median duration of 7 months, a phase 2 active comparator study now underway.

The acquisition aims to create a new patient acquisition channel by connecting aesthetic practices with corporate skin health and wellness programs.